AstraZeneca PLC (AZN)
| Market Cap | 242.25B |
| Revenue (ttm) | 49.13B |
| Net Income (ttm) | 6.44B |
| Shares Out | 3.10B |
| EPS (ttm) | 2.07 |
| PE Ratio | 38.21 |
| Forward PE | 16.31 |
| Dividend | $1.45 (1.86%) |
| Ex-Dividend Date | Feb 22, 2024 |
| Volume | 5,827,853 |
| Open | 78.48 |
| Previous Close | 78.52 |
| Day's Range | 78.08 - 79.45 |
| 52-Week Range | 60.47 - 80.86 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 87.25 (+11.67%) |
| Earnings Date | Jul 25, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $87.25, which is an increase of 11.67% from the latest price.
News
Europe's Markets Are Cheap. 4 Stocks to Play.
Nevertheless, its member economies are poised for a rebound.
AstraZeneca's CEO talks earnings, competition, China, and potential tariffs
AstraZeneca (AZN) reported a second-quarter earnings beat, raising their full-year guidance due to strong demand. However, the company faced some pressure in areas like operating costs.
Govt body's procedures means people with cancer aren't getting drug - AstraZeneca boss
The chief executive of AstraZeneca has criticised a public health body for refusing to make one of its breast cancer treatments available to NHS patients in England and Wales.
AstraZeneca CEO on revenue beat
AstraZeneca CEO Pascal Soriot joins 'Squawk on the Street' to discuss the company's quarterly earnings results, its goal to double sales by 2030, and its Farxiga drug.
AstraZeneca Lifts Guidance as Demand for Cancer Drugs Grows
Aradhana Sarin, Chief Financial Officer, at AstraZeneca, joins Bloomberg Intelligence to discuss company earnings and their 2030 projections.
AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales
AstraZeneca (AZN) posted better-than-expected results for the second quarter and lifted its full-year guidance Thursday as revenue grew in nearly all of its product categories compared to the same tim...
AstraZeneca's H1 and Q2 2024 Financial Results
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--H1/Q2 2024 Earnings Release (25 July 2024).
AstraZeneca lifts full-year outlook on upbeat demand for therapies
Anglo-Swedish drugmaker AstraZeneca on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer ...
These Stocks Offer Gains Without the U.S. Political Drama
Keir Stamer's style is the polar opposite of Donald Trump. Many wondered if he was too boring to be U.K. Prime Minister.
AstraZeneca Closes Acquisition of Amolyt Pharma
LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrin...
AstraZeneca's COVID prevention drug application gets EU fast-track assessment
AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infecti...
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines
KIRKLAND, Wash.--(BUSINESS WIRE)--Tanium today shared the success story of customer AstraZeneca in securing over 125,000 endpoints across 125 countries using the Tanium XEM platform.
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company s...
AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
AstraZeneca's breast cancer drug combination fails in late-stage trial
AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patient...
AstraZeneca's lung cancer drug approved by US FDA for combination chemotherapy treatment
AstraZeneca, the largest pharmaceutical group in Britain, announced that the U.S. Food and Drug Administration (FDA) has approved its lung cancer drug, Imfinzi, for use alongside other chemotherapy tr...
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with carboplatin and paclitaxel followed by IMFINZI monotherapy has been approved in the US as treatment for adult...
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer tha...
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 d...
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult...
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment
ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closi...
We're in a difficult business but have the right level of confidence, says AstraZeneca CEO
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.